<html><head><style>div {border : red solid 0.5px}</style><style>span {border : blue dotted 0.5px}</style></head><body><div left="72.0" right="540.72" top="705.52"><span x0="72.0" y0="705.52" x1="540.72" style="x0: 72.0; x1: 78.0; y0: 705.52; y1: 717.52; width: 6.0; font-size: 12.0; font-family: TNXFRR+TimesNewRomanPSMT;">underscored by the so-called &#8220;90/10&#8221; gap involving the development of medicines, vaccines, and </span></div><div left="72.0" right="174.24" top="677.92"><span x0="72.0" y0="677.92" x1="174.24" style="x0: 72.0; x1: 75.34; y0: 677.92; y1: 689.92; width: 3.34; font-size: 12.0; font-family: TNXFRR+TimesNewRomanPSMT;">treatments for which </span><span x0="174.29" y0="677.92" x1="244.73" style="x0: 174.29; x1: 177.62; y0: 677.92; y1: 689.92; width: 3.34; font-size: 12.0; font-family: IUNRTN+TimesNewRomanPS-ItalicMT;">less than 10% </span><span x0="244.73" y0="677.92" x1="495.72" style="x0: 244.73; x1: 250.73; y0: 677.92; y1: 689.92; width: 6.0; font-size: 12.0; font-family: TNXFRR+TimesNewRomanPSMT;">of US annual health-research spending is tied to the </span></div><div left="72.0" right="538.32" top="650.32"><span x0="72.0" y0="650.32" x1="538.32" style="x0: 72.0; x1: 78.0; y0: 650.32; y1: 662.32; width: 6.0; font-size: 12.0; font-family: TNXFRR+TimesNewRomanPSMT;">healthcare interests of 90% of the world&#8217;s population (WHO 2002, p. 23).  The 90/10 gap means </span></div><div left="72.0" right="540.48" top="622.72"><span x0="72.0" y0="622.72" x1="540.48" style="x0: 72.0; x1: 75.34; y0: 622.72; y1: 634.72; width: 3.34; font-size: 12.0; font-family: TNXFRR+TimesNewRomanPSMT;">that there is an imbalance of best-shot health GPGs that primarily favors rich-countries diseases.  </span></div><div left="72.0" right="540.72" top="595.12"><span x0="72.0" y0="595.12" x1="540.72" style="x0: 72.0; x1: 80.66; y0: 595.12; y1: 607.12; width: 8.66; font-size: 12.0; font-family: TNXFRR+TimesNewRomanPSMT;">Given differences in life expectancy, lifestyles, healthcare infrastructure, population age profiles, </span></div><div left="72.0" right="530.4" top="567.52"><span x0="72.0" y0="567.52" x1="530.4" style="x0: 72.0; x1: 78.0; y0: 567.52; y1: 579.52; width: 6.0; font-size: 12.0; font-family: TNXFRR+TimesNewRomanPSMT;">nutrition, education, immunization programs, and economic development, people in developed </span></div><div left="72.0" right="536.09" top="539.92"><span x0="72.0" y0="539.92" x1="536.09" style="x0: 72.0; x1: 77.33; y0: 539.92; y1: 551.92; width: 5.33; font-size: 12.0; font-family: TNXFRR+TimesNewRomanPSMT;">countries generally suffer from noncommunicable &#8220;old age&#8221; diseases, while those in developing </span></div><div left="72.0" right="528.72" top="512.32"><span x0="72.0" y0="512.32" x1="528.72" style="x0: 72.0; x1: 77.33; y0: 512.32; y1: 524.32; width: 5.33; font-size: 12.0; font-family: TNXFRR+TimesNewRomanPSMT;">countries typically suffer from infectious and parasitic diseases.  With these differences, donor </span></div><div left="72.0" right="535.32" top="484.72"><span x0="72.0" y0="484.72" x1="535.32" style="x0: 72.0; x1: 77.33; y0: 484.72; y1: 496.72; width: 5.33; font-size: 12.0; font-family: TNXFRR+TimesNewRomanPSMT;">countries and their constituency face a difficulty in understanding the health GPG needs of poor </span></div><div left="72.0" right="122.04" top="457.12"><span x0="72.0" y0="457.12" x1="122.04" style="x0: 72.0; x1: 77.33; y0: 457.12; y1: 469.12; width: 5.33; font-size: 12.0; font-family: TNXFRR+TimesNewRomanPSMT;">countries. </span></div><div left="108.0" right="508.68" top="429.52"><span x0="108.0" y0="429.52" x1="508.68" style="x0: 108.0; x1: 115.33; y0: 429.52; y1: 441.52; width: 7.33; font-size: 12.0; font-family: TNXFRR+TimesNewRomanPSMT;">The problem is compounded by the pharmaceutical companies whose research and </span></div><div left="72.0" right="541.8" top="401.92"><span x0="72.0" y0="401.92" x1="541.8" style="x0: 72.0; x1: 78.0; y0: 401.92; y1: 413.92; width: 6.0; font-size: 12.0; font-family: TNXFRR+TimesNewRomanPSMT;">development is motivated by profit.  As a consequence, those firms want to develop medicines to </span></div><div left="72.0" right="534.48" top="374.32"><span x0="72.0" y0="374.32" x1="534.48" style="x0: 72.0; x1: 75.34; y0: 374.32; y1: 386.32; width: 3.34; font-size: 12.0; font-family: TNXFRR+TimesNewRomanPSMT;">treat cancers, heart disease, and hepatitis C.  Pharmaceutical firms&#8217; profits are higher when they </span></div><div left="72.0" right="531.48" top="346.72"><span x0="72.0" y0="346.72" x1="531.48" style="x0: 72.0; x1: 78.0; y0: 346.72; y1: 358.72; width: 6.0; font-size: 12.0; font-family: TNXFRR+TimesNewRomanPSMT;">develop treatment regimes rather than vaccines.  With vaccines, one or two doses are sufficient </span></div><div left="72.0" right="500.4" top="319.12"><span x0="72.0" y0="319.12" x1="500.4" style="x0: 72.0; x1: 75.34; y0: 319.12; y1: 331.12; width: 3.34; font-size: 12.0; font-family: TNXFRR+TimesNewRomanPSMT;">to keep the disease at bay, so that per-patient revenue streams are low unlike the case for </span></div><div left="72.0" right="525.72" top="291.52"><span x0="72.0" y0="291.52" x1="525.72" style="x0: 72.0; x1: 75.34; y0: 291.52; y1: 303.52; width: 3.34; font-size: 12.0; font-family: TNXFRR+TimesNewRomanPSMT;">treatment regimes with a continual revenue stream.  Pharmaceutical firms pursue drugs where </span></div><div left="72.0" right="496.44" top="263.92"><span x0="72.0" y0="263.92" x1="496.44" style="x0: 72.0; x1: 75.34; y0: 263.92; y1: 275.92; width: 3.34; font-size: 12.0; font-family: TNXFRR+TimesNewRomanPSMT;">there is high income elasticity and low price elasticity, which corresponds to life-saving </span></div><div left="72.0" right="207.6" top="236.32"><span x0="72.0" y0="236.32" x1="207.6" style="x0: 72.0; x1: 81.34; y0: 236.32; y1: 248.32; width: 9.34; font-size: 12.0; font-family: TNXFRR+TimesNewRomanPSMT;">medicines in rich countries. </span></div><div left="108.0" right="508.44" top="208.72"><span x0="108.0" y0="208.72" x1="508.44" style="x0: 108.0; x1: 115.33; y0: 208.72; y1: 220.72; width: 7.33; font-size: 12.0; font-family: TNXFRR+TimesNewRomanPSMT;">The typical shortfall associated with public goods as countries act independently is </span></div><div left="72.0" right="529.8" top="181.12"><span x0="72.0" y0="181.12" x1="529.8" style="x0: 72.0; x1: 77.33; y0: 181.12; y1: 193.12; width: 5.33; font-size: 12.0; font-family: TNXFRR+TimesNewRomanPSMT;">especially worrying for health GPGs because of the vastly different threats posed by infectious </span></div><div left="72.0" right="517.8" top="153.52"><span x0="72.0" y0="153.52" x1="517.8" style="x0: 72.0; x1: 77.33; y0: 153.52; y1: 165.52; width: 5.33; font-size: 12.0; font-family: TNXFRR+TimesNewRomanPSMT;">and non-infectious diseases to poor and rich countries, respectively.  Rich countries with the </span></div><div left="72.0" right="536.16" top="125.92"><span x0="72.0" y0="125.92" x1="536.16" style="x0: 72.0; x1: 81.34; y0: 125.92; y1: 137.92; width: 9.34; font-size: 12.0; font-family: TNXFRR+TimesNewRomanPSMT;">means to provide best-shot GPGs are not motivated to do so if they can protect themselves from </span></div><div left="72.0" right="178.68" top="98.32"><span x0="72.0" y0="98.32" x1="178.68" style="x0: 72.0; x1: 77.33; y0: 98.32; y1: 110.32; width: 5.33; font-size: 12.0; font-family: TNXFRR+TimesNewRomanPSMT;">a spreading infection. </span></div></body></html>